Future Drug Discovery: best of 2019

Future Drug Discovery Editor, Jenny Straiton, takes a look back at 2019 in the journal.

Like Comment

Launched in July of 2019, Future Drug Discovery is RxNet’s newest partner journal. Here, Editor Jenny Straiton summarizes the top five most-read articles from the journal’s inaugural volume and discusses the exciting new projects to come in 2020.

Content highlights

Starting things off, our number one most-read article comes from a team at the University of Minnesota (USA); Vidhi Khanna et al. describe their study investigating a pair of previously developed antibodies as targeting ligands for nanoparticle-mediated drug delivery. Designed to target the cell surface protein perlecan, the antibody–nanoparticle conjugates showed improved cell uptake, retention and cytotoxicity in vitro as well as enhanced tumor growth inhibition in vivo.

Next, we have a pair of interviews, both of which were also featured here on RxNet. First, Anthony Coates (Helperby Therapeutics; London, UK) discussed the future of antibiotic therapies, why this is such an important field and how we could go about overcoming antimicrobial resistance. Second, two ex-pharma employees discuss the move from Big pharma to a contract research organization (CRO). Ian Waddell and Chris Hill (both of Charles River Laboratories; Cambridge, UK) commented on their decision to move into the CRO sector, their expectations when first making the jump and what they’ve found most exciting whilst working there.

Taking spot number four is the first article ever published in Future Drug Discovery; Giulia Caron (Università degli Studi di Torino; Torino, Italy) and colleagues investigate the experimental lipophilicity of beyond Rule of 5 compounds (bRo5), utilizing a chromatographic strategy for the determination of log P for bRo5 drugs. The results demonstrate that this strategy, known as BRlogP, is a valuable and fast tool to experimentally access lipophilicity of neutral bRo5 compliant compounds. When used in combination with the tool ElogP, it can provide an experimental log P range that has potential for implementation in novel bRo5 drug discovery programs.

Finally, we have a commentary by Xingcai Zhang (Harvard University; MA, USA) et al., reviewing developments in metal polyphenol nanonetwork self-assembly technology as well as its various drug delivery and pharmaceutical applications. Discussing both the potential the technology holds, as well as the challenges it has still to overcome, the review provides an overview on the current status of the technology. Though not holding the top spot for most page views, this article does have the highest number of citations.

Themes of 2020

As it was the launch year, only two issues were published in volume 1 of Future Drug Discovery. However, we did have our first themed issue, covering the topic of artificial intelligence in drug discovery. With editorials from Rae Lawrence (Cancer Research UK Manchester Institute; UK), Edmon Begoli (Oak Ridge National Laboratory; TN, USA) and Dimitri Kusnezov (US Department of Energy; DC, USA), the issue covered a wide range of opinions to cover this controversial topic.

In 2020, we have more exciting themed issues planned. Starting with immuno-oncology and then going on to drug repurposing, anti-microbial resistance and computer-aided drug design, we hope to cover all aspects of the drug discovery pipeline. If you have any ideas for these issues, please get in touch.

Early Career Panel

We are hugely thankful to our excellent Editorial Board, who provide valuable support with their contributions. As we enter 2020, we are hopeful to expand that board to incorporate an Early Career Panel who may support our board members and advance their own careers. Open to any individual within the first 6 years of their first academic or industrial appointment, we are recruiting members now! If you are interested in joining the panel then please get in touch for more information.

Join our Early Career Panels

RxNet Partnership

We are excited to continue our partnership with RxNet and members will continue to get exclusive access to content. A great example of this was our first ‘Peek behind the Paper’ interview with author Jürgen Bajorath (University of Bonn, Germany) where he commented on his recent Future Drug Discovery paper discussing a novel compound optimization monitor method. We look forward to providing RxNet members with more content like this.

Another highlight of our partnership has to be the RxNet Glossary of Drug Discovery, published earlier this year. Thanks to our joint Expert Panel, we compiled a list of all the key terms used in drug discovery and gave a handy definition for your reference. Be sure to watch out for which conferences RxNet will be attending so you can pick up your copy.

That is it for the Future Drug Discovery round up of 2019. All of the articles mentioned are available to view open access. If you are interested in finding out more about Future Drug Discovery or wish to submit your research, visit our website or get in touch with one of our Editors today

Go to the profile of Future Drug Discovery

Future Drug Discovery

Journal , Future Science Group

Future Drug Discovery is a peer-reviewed journal covering the latest breakthrough science in drug discovery, research & development. The journal strives to drive drug discovery by taking a multi-disciplinary and forward-looking stance, presenting new advances and discussing their applications and translation. Future Drug Discovery will also be a forum for discussing the field at large.

No comments yet.